These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 27341596)

  • 1. Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors.
    Kircher SM; Nimeiri HS; Benson AB
    Cancer J; 2016; 22(3):182-9. PubMed ID: 27341596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?
    Karasic TB; Rosen MA; O'Dwyer PJ
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):661-671. PubMed ID: 28721456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
    Venook AP
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
    [No Abstract]   [Full Text] [Related]  

  • 4. Regorafenib in metastatic colorectal cancer.
    Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
    Papadimitriou M; Papadimitriou CA
    Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis in Colorectal Cancer: Antibodies.
    Chan E
    Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.
    Aprile G; Macerelli M; Giuliani F
    BioDrugs; 2013 Jun; 27(3):213-24. PubMed ID: 23435872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.
    Lee YC; Michael M; Zalcberg JR
    Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic Therapy in Colorectal Cancer.
    Mody K; Baldeo C; Bekaii-Saab T
    Cancer J; 2018; 24(4):165-170. PubMed ID: 30119079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis.
    Chebib R; Verlingue L; Cozic N; Faron M; Burtin P; Boige V; Hollebecque A; Malka D
    Semin Oncol; 2017 Apr; 44(2):114-128. PubMed ID: 28923209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of regorafenib and its current and potential future role in cancer therapy.
    Davis SL; Eckhardt SG; Messersmith WA; Jimeno A
    Drugs Today (Barc); 2013 Feb; 49(2):105-15. PubMed ID: 23462625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
    Khan K; Cunningham D; Chau I
    Curr Drug Targets; 2017; 18(1):56-71. PubMed ID: 25808652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
    Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
    Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
    [No Abstract]   [Full Text] [Related]  

  • 15. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
    Kato S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
    Collins TS; Hurwitz HI
    Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib as treatment for patients with advanced hepatocellular cancer.
    Thillai K; Srikandarajah K; Ross P
    Future Oncol; 2017 Oct; 13(25):2223-2232. PubMed ID: 28766967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib induces adaptive resistance of colorectal cancer cells via inhibition of vascular endothelial growth factor receptor.
    Tomida C; Nagano H; Yamagishi N; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    J Med Invest; 2017; 64(3.4):262-265. PubMed ID: 28954993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multikinase inhibitor regorafenib offers an efficient therapeutic alternative].
    Rev Med Suisse; 2014 May; 10(431):1108. PubMed ID: 24941678
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.